Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| FB Forlong BiotechnologyCompany profile Clinical-stage biotech developing cytokine therapies including IL-15 and IL-18 programs for cancer Clinical-stage biotech developing cytokine therapies including IL-15 and IL-18 programs for cancer | $17.5M | Pre-Series BUndisclosed | Biotech | China | Investors | |
| PB ProEncia BiotechnologyCompany profile Develops non-invasive periodontal care products for patients with periodontal disease Develops non-invasive periodontal care products for patients with periodontal disease | Undisclosed | Pre-SeedPre-seed | Biotech | United States | Investors Undisclosed | |
| CH Century HealthCompany profile Automates curation and enrichment of real-world clinical data for pharmaceutical and life sciences research Automates curation and enrichment of real-world clinical data for pharmaceutical and life sciences research | $5M | Seed | Biotech, Healthtech | United States | Investors | |
| AB Accro BioscienceCompany profile Clinical-stage medicines targeting inflammation and regulated cell-death pathways in immune-mediated disease. Clinical-stage medicines targeting inflammation and regulated cell-death pathways in immune-mediated disease. | $50M | Series CSeries C+ | Biotech | United States | Investors | |
| FT Full-Life TechnologiesCompany profile Clinical-stage radiotherapeutics company developing targeted cancer therapies with integrated isotope manufacturing Clinical-stage radiotherapeutics company developing targeted cancer therapies with integrated isotope manufacturing | $150M | Series D+DebtUndisclosed | Biotech | China | Investors | |
| VT Violet TherapeuticsCompany profile Develops first-in-class small molecule therapies for neurodegenerative disease via glial cell signaling platform Develops first-in-class small molecule therapies for neurodegenerative disease via glial cell signaling platform | $4.8M | Seed+Seed | Biotech | United States | Investors | |
| A AlcolaseCompany profile Alcolase is developing a liposomal enzyme system intended to break down alcohol in the stomach before absorption. Alcolase is developing a liposomal enzyme system intended to break down alcohol in the stomach before absorption. | €1.5M | Undisclosed | Biotech | Denmark | Investors | |
| WB Wonderlab BioCompany profile Makes off-the-shelf iPSC-derived cell therapies using HLA-matched super donors for broad patient access Makes off-the-shelf iPSC-derived cell therapies using HLA-matched super donors for broad patient access | Undisclosed | StrategicUndisclosed | Biotech | United States | Investors | |
| CM CREATE MedicinesCompany profile Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies | $122M | Series B | Biotech | United States | Investors | |
| DT Degron TherapeuticsCompany profile Develops molecular glue degrader medicines targeting previously undruggable proteins Develops molecular glue degrader medicines targeting previously undruggable proteins | $40M | Series A+Series A | Biotech | China | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.